Literature DB >> 17566685

Small hepatocellular carcinomas in cirrhosis: differences in contrast enhancement effects between helical CT and MR imaging during multiphasic dynamic imaging.

Minoru Hayashida1, Katsuyoshi Ito, Takeshi Fujita, Ayame Shimizu, Katsumi Sasaki, Masahiro Tanabe, Naofumi Matsunaga.   

Abstract

PURPOSE: The purpose of this study was to evaluate differences in the degrees of contrast enhancement effects of small hepatocellular carcinomas (HCCs) in patients with cirrhosis between helical computed tomography (CT) and magnetic resonance (MR) imaging during multiphasic contrast-enhanced dynamic imaging and to determine the diagnostic value of MR imaging especially in assessing hypovascular HCCs detected as hypoattenuating nodules on late-phase CT. SUBJECTS AND METHODS: This study included 64 small HCCs (<3 cm in diameter) in 40 patients with chronic hepatitis or cirrhosis who underwent multiphasic (arterial, portal and late phases) contrast-enhanced dynamic helical CT and MR imaging. The contrast enhancement patterns of each lesion in the arterial and late phases were evaluated by two radiologists experienced in liver MR imaging and categorized as one of five grades (1=hypoattenuated/hypointense; 2=slightly hypoattenuated/hypointense; 3=isoattenuated/isointense; 4=slightly hyperattenuated/hyperintense; 5=hyperattenuated/hyperintense), compared with the surrounding liver parenchyma. RESULT: Forty-three (67%) of 64 lesions showed Grade 4 (n=24) or Grade 5 (n=19) enhancement on arterial-phase CT, while 51 (80%) of 64 lesions showed Grade 4 (n=20) or Grade 5 (n=31) enhancement on arterial-phase MR imaging, indicating hypervascular HCCs. The grading score of hypervascular HCCs on arterial-phase MR imaging (mean: 4.61) was significantly (P<.01) higher than that for hypervascular HCCs on arterial-phase CT (mean: 4.20), showing better detection of the hypervascularity (arterial enhancement) of the lesion on arterial-phase MR imaging. Regarding hypovascular HCCs, all (100%) of 21 hypovascular HCCs on CT showed Grade 1 (n=10) or Grade 2 (n=11) enhancement on late-phase CT, seen as hypoattenuation. In contrast, 8 (62%) of 13 hypovascular HCCs on MR imaging showed Grade 1 (n=1) or Grade 2 (n=7) enhancement on late-phase MR imaging, seen as hypointensity. Grading scores of hypovascular HCCs on late-phase images were significantly (P<.001) lower on CT than on MR imaging (mean score: 1.52 vs. 2.31), indicating better washout effects for hypovascular HCCs on late-phase CT.
CONCLUSION: The washout effects for small HCCs on late-phase MR imaging were inferior to those for small HCCs on late-phase CT. Especially, hypovascular HCCs demonstrated as hypoattenuating nodules on late-phase CT were often not seen on late-phase MR imaging, requiring careful evaluation of other sequences, including unenhanced T(1)-weighted and T(2)-weighted MR images.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17566685     DOI: 10.1016/j.mri.2007.04.007

Source DB:  PubMed          Journal:  Magn Reson Imaging        ISSN: 0730-725X            Impact factor:   2.546


  8 in total

Review 1.  Functional imaging of hepatocellular carcinoma.

Authors:  Tim Ch Hoogenboom; Mark Thursz; Eric O Aboagye; Rohini Sharma
Journal:  Hepat Oncol       Date:  2016-03-29

2.  Does a combined CT and MRI protocol enhance the diagnostic efficacy of LI-RADS in the categorization of hepatic observations? A prospective comparative study.

Authors:  Mohammad Abd Alkhalik Basha; Mohamad Zakarya AlAzzazy; Ayman F Ahmed; Hala Y Yousef; Samar Mohamad Shehata; Dena Abd El Aziz El Sammak; Talaat Fathy; Ahmed Ali Obaya; Eman H Abdelbary
Journal:  Eur Radiol       Date:  2018-01-24       Impact factor: 5.315

3.  Primary clear cell carcinoma in the liver: CT and MRI findings.

Authors:  Qing-Yu Liu; Hai-Gang Li; Ming Gao; Xiao-Feng Lin; Yong Li; Jian-Yu Chen
Journal:  World J Gastroenterol       Date:  2011-02-21       Impact factor: 5.742

4.  Current limitations and potential breakthroughs for the early diagnosis of hepatocellular carcinoma.

Authors:  Myeong-Jin Kim
Journal:  Gut Liver       Date:  2011-03-16       Impact factor: 4.519

Review 5.  The diagnostic performance of contrast-enhanced CT versus extracellular contrast agent-enhanced MRI in detecting hepatocellular carcinoma: direct comparison and a meta-analysis.

Authors:  Xi Chen; Mingkai Li; Ruomi Guo; Weimin Liu; Jianwen Li; Xiaodan Zong; Qilong Chen; Jin Wang
Journal:  Abdom Radiol (NY)       Date:  2022-03-21

6.  Gadoxetic acid-enhanced MRI for hepatocellular carcinoma and hypointense nodule observed in the hepatobiliary phase.

Authors:  Elsa Iannicelli; Marco Di Pietropaolo; Massimo Marignani; Chiara Briani; Giulia Francesca Federici; Gianfranco Delle Fave; Vincenzo David
Journal:  Radiol Med       Date:  2013-12-03       Impact factor: 3.469

7.  Added value of subtraction imaging in detecting arterial enhancement in small (<3 cm) hepatic nodules on dynamic contrast-enhanced MRI in patients at high risk of hepatocellular carcinoma.

Authors:  Chansik An; Mi-Suk Park; Dowhan Kim; Yeo-Eun Kim; Woo-Suk Chung; Hyungjin Rhee; Myeong-Jin Kim; Ki Whang Kim
Journal:  Eur Radiol       Date:  2012-11-09       Impact factor: 5.315

8.  Added value of Gd-EOB-DTPA-enhanced Hepatobiliary phase MR imaging in evaluation of focal solid hepatic lesions.

Authors:  Michael Haimerl; Max Wächtler; Ivan Platzek; Rene Müller-Wille; Christoph Niessen; Patrick Hoffstetter; Andreas Georg Schreyer; Christian Stroszczynski; Philipp Wiggermann
Journal:  BMC Med Imaging       Date:  2013-12-01       Impact factor: 1.930

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.